Viatris CEO Won't Guide 2027 But Calls Analyst's EBITDA Math 'In The Ballpark'
Scott Smith said the company is making "tremendous progress" toward its 2030 targets, while a halted Indian plant cost about $100 million in third-quarter revenue.
Viatris CEO Scott Smith refused to give 2027 guidance on the drugmaker's earnings call Thursday, but said an Evercore ISI analyst's EBITDA figures for as early as 2027 are "certainly in the ballpark of where we may be going." Viatris, a global healthcare company that sells generics, brand-name drugs and a growing range of innovative medicines, reported third-quarter adjusted EBITDA of $1.2 billion on revenue of $3.75 billion.
A 2030 target, pulled forward
The Evercore ISI analyst asked whether $5 billion of EBITDA could be within reach as early as 2027 rather than 2030. Smith said the company is
Pacira and the 2027 math
Smith said the planned Pacira Biosciences purchase would lift U.S. innovative medicines revenue to more than a billion dollars in 2027. Interim CFO Paul Campbell said the deal should be immediately accretive, meaning it adds to earnings, across all 2027 guidance metrics versus expected 2026 results.
Campbell said the 2026 outlook excludes Pacira. The tender offer launched October 30, and Viatris expects to close before the end of November, funding it from excess cash and short-term borrowings. He said the company expects more than $50 million in annual cost synergies by the end of 2028.
Campbell also flagged 2027 headwinds: a possible mid-year loss of exclusivity for a Japan product, and a full-year hit from Isosulfan Blue, which lost exclusivity in the U.S. this year.
Nashik halt and a shifting year
Supply constraints tied to remediation at the Nashik facility cut third-quarter revenue by about $100 million, Campbell said. The FDA classified the plant as official action indicated in September, after observations issued in May, and Viatris suspended manufacturing there in October as a precaution.
Campbell said original 2026 guidance had North America flat and Europe up 4%. At the midpoints of updated guidance, North America is now in the high single digits and Europe is flattish, with supply problems and competition on some products.
On the quarter, North America net sales grew about 7% and Greater China about 10%. Viatris raised the midpoints of its 2026 guidance again, with nine-month adjusted EBITDA up 6%.
The FDA's decision date for fast-acting meloxicam is December 27, and Viatris expects the Pacira deal to close before the end of November.
Sources
- Viatris Q3 Earnings Beat on Stronger Margins, Revenues Fall Y/Y — Yahoo Finance
- This Former Mylan/Pfizer Combo Just Topped Its Buy Zone — What You Should Know | Investor's Business Daily — investors.com
- Viatris in charts: Revenue remains stable at $3.75B as Greater China leads regional growth | Seeking Alpha — seekingalpha.com
- Earnings Snapshot: Viatris lifts annual outlook as Q3 revenue edges below expectations | Seeking Alpha — seekingalpha.com
- Viatris: Q3 Earnings Snapshot | wusa9.com — Associated Press